Default company panoramic image

Arrien Pharmaceuticals

Arrien Pharmaceutical’s is a new drug discovery company. Series A invested $ 2 million by founders. Seeking $10 million Series B by Q4 2014.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Salt Lake City, UT, USA
  • Currency USD
  • Founded January 2011
  • Employees 12
  • Website

Company Summary

Arrien Pharmaceutical’s is a Pre-Clinical‐stage Biopharmaceutical company focused on the design and development of targeted novel small molecule First‐in Class Therapeutics using its proprietary FIELDS platform. Company currently focused on Rheumatoid Arthritis (RA), Multiples Sclerosis (MS), Psoriasis, Cancer (Ovarian, Breast, Prostate, DLBCL, Lung and GBM), Parkinson's, and Diabesity Diseases.


  • Default avatar
    Hariprasad Vankayalapati
    Chief Scientific Officer

    Dr. Hari currently serving as Chief Scientific Officer/Scientific Advisor of Arrien Pharmaceuticals. Dr. Hari has held positions of increasing responsibility on CNS, Cancer, Inflammation and Diabesity therapeutics development at Arrien Pharmaceuticals since he founded the company in January 2011. He is also serving as Assistant Professor in Medicinal Chemistry at the Center for Investigational Therapeutics (CIT) of The Huntsman Cancer Institute a

  • Default avatar
    Rajendra P Appalaneni
    Executive Officer

    Mr. Rajendra is the Chairman and Executive Officer of Arrien Pharmaceuticals. Mr. Rajendra demonstrated the ability to invest own money, lead diverse teams of professionals to new levels of success in a variety of highly competitive industries, cutting-edge markets, and fast-paced environments. He has strong business development experience with an impressive track record of more than 14 years of hands-on experience in strategic planning, project


  • Default avatar
    Camille DeGalan
    Default avatar
    Chantal Katz

Previous Investors

  • Default avatar
    Founder of the Company